Amazentis Sa

Ecole Polytechnique Federale De Lausanne

Tes Pharma S.r.l.

Johan Auwerx

Laurent Mouchiroud

Christopher Rinsch

Penelope Andreux

William Blanco-Bose

Bernard Schneider

Carmen Sandi

Eija Pirinen

David Genoux

Richardus Houtkooper

Charles Thomas

Dongryeol Ryu

Roberto Pellicciari

Nadia Raffaelli

Hongbo Zhang

Riekelt Houtkooper

Peter Bai

Carlos Canto Alvarez

Keir Menzies

Pénélope Andreux

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Enhancing autophagy or increasing longevity by administration of urolithins

Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

The present disclosure discloses compounds capable of modulating the activity of &#x3b1;-amino-&#x3b2;-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NADbiosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase

The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of muscle stem senescence.

Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

The present invention provides methods of treating various disorders associated with mitochondrial dysfunction, including but not limited to metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, and diseases of aging.

Methods of treating mitochondrial dysfunction

Growing community of inventors

Buchillon, Switzerland

Johan Auwerx